Developing innovative treatments designed to improve the everyday lives of women and men
Driving Innovative Research
We aim to develop a targeted approach for diseases of high unmet medical need. Our team is committed to bringing much-needed attention and innovation to women’s health and prostate cancer.
– Lynn Seely, MD, President and Chief Executive Officer
For too long, patients have suffered in the shadows. We are bringing this issue to the light and fighting for a brighter future."
20 Aug 2019
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
6 Aug 2019
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
23 Jul 2019
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
22 Jul 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study